Maarten Cozijnsen

136 37. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52- 65 38. Awni WM, Eckert D, Sharma S, et al. Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis. Gastroenterology. 2013;144:S229 39. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430-1436 40. Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. InflammBowel Dis. 2013;19:1065- 1072 41. Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. J Gastroenterol Hepatol. 2014;29:1177-1185 42. Jeuring S, Van Den Heuvel T, Romberg-Camps M, et al. Concomitant use of immunomodulators increases long term response to infliximab in ulcerative colitis-a population-based IBD-SL cohort study. Gastroenterology. 2013;144:S431 43. Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013;7:717-722 44. Rosh J, Ruemmele F, Dubinsky M, et al. Long-term safety of adalimumab in paediatric patients with Crohn’s disease. 9th Congress of ECCO, P426; 2014 45. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063 46. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146:941-949 47. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in crohn’s disease: Results from the TREAT(trademark) registry. Am J Gastroenterol. 2014;109:212-223 48. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146-2153 49. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99-105